| |
n=19 |
% |
| Characteristics |
|
|
| Median age, years (range) |
54 |
(40-78) |
| Sex, male/female |
9/10 |
|
| ECOG performance status: 0/1/2 |
9/9/1 |
|
| Primary site: Colon/Rectum |
8/11 |
|
| Advanced/Recurrence |
9/10 |
|
| Metastasis site: |
Liver |
11 |
(57.9%) |
| |
Lung |
11 |
(57.9%) |
| |
Lymph Nodes |
10 |
(52.6%) |
| |
Peritoneum |
7 |
(36.8%) |
| |
Other |
7 |
(36.8%) |
| Metastasis sites>2 |
15 |
(78.9%) |
| Median number of prior chemotherapies (range) |
3 |
(1-5) |
| Oxaliplatin-containing regimen |
18 |
(94.7%) |
| Irinotecan-containing regimen |
18 |
(94.7%) |
| Bevacizumab-containing regimen |
13 |
(68.4%) |
| Cetuximab-containing regimen |
19 |
(100%) |
| Outcome |
|
|
| Complete response |
0 |
(0%) |
| Partial response |
0 |
(0%) |
| Stable disease (SD) |
5 |
(29.2%) |
| Progressive disease |
12 |
(54.2%) |
| Not evaluable |
2 |
(12.5%) |
| Long SD |
4 |
(21.1%) |
Long SD: stable disease for more than 120 days.